Hayashi Y, Ueyama A, Funaki S, Jinushi K, Higuchi N, Morihara H
BMC Cancer. 2024; 24(1):627.
PMID: 38783281
PMC: 11112935.
DOI: 10.1186/s12885-024-12363-x.
Dwivedi M, Tiwari S, Kemp E, Begum R
Heliyon. 2022; 8(8):e10450.
PMID: 36082331
PMC: 9445387.
DOI: 10.1016/j.heliyon.2022.e10450.
Grimmett E, Al-Share B, Alkassab M, Zhou R, Desai A, Rahim M
Discov Oncol. 2022; 13(1):31.
PMID: 35576080
PMC: 9108694.
DOI: 10.1007/s12672-022-00491-4.
Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K
Nat Commun. 2021; 12(1):7280.
PMID: 34907192
PMC: 8671535.
DOI: 10.1038/s41467-021-27574-0.
Liu J, Wang Y, Yuan S, Wei J, Bai J
Front Immunol. 2021; 12:751594.
PMID: 34745124
PMC: 8564196.
DOI: 10.3389/fimmu.2021.751594.
The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer.
Iwamoto G, Kawahara T, Yokomizo Y, Miyoshi Y, Yao M, Uemura H
Asian J Urol. 2021; 8(3):332-334.
PMID: 34401340
PMC: 8356057.
DOI: 10.1016/j.ajur.2020.05.006.
Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma.
Davidsson S, Fiorentino M, Giunchi F, Eriksson M, Erlandsson A, Sundqvist P
Eur Urol Open Sci. 2021; 20:62-71.
PMID: 34337459
PMC: 8317874.
DOI: 10.1016/j.euros.2020.06.003.
Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them?.
Cinier J, Hubert M, Besson L, Di Roio A, Rodriguez C, Lombardi V
Cancers (Basel). 2021; 13(8).
PMID: 33924428
PMC: 8069615.
DOI: 10.3390/cancers13081850.
Development of Therapeutic Vaccines for Ovarian Cancer.
Chow S, Berek J, Dorigo O
Vaccines (Basel). 2020; 8(4).
PMID: 33167428
PMC: 7711901.
DOI: 10.3390/vaccines8040657.
Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville V, Metheringham R, Daniels I, Atabani S, Symonds P, Cook K
J Immunother Cancer. 2020; 8(1).
PMID: 32561639
PMC: 7304843.
DOI: 10.1136/jitc-2020-000560.
Comprehensive Analysis of Tumor-Infiltrating Immune Cells and Relevant Therapeutic Strategy in Esophageal Cancer.
Lu G, Chen L, Wu S, Feng Y, Lin T
Dis Markers. 2020; 2020:8974793.
PMID: 32454908
PMC: 7238334.
DOI: 10.1155/2020/8974793.
Combined CD44- and CD25-Targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T Cells in Syngeneic Mouse Cancer Models.
Maruoka Y, Furusawa A, Okada R, Inagaki F, Fujimura D, Wakiyama H
Cancer Immunol Res. 2020; 8(3):345-355.
PMID: 31953245
PMC: 8477607.
DOI: 10.1158/2326-6066.CIR-19-0517.
Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.
Lim E, Okkenhaug K
Immunology. 2019; 157(3):210-218.
PMID: 31107985
PMC: 6587315.
DOI: 10.1111/imm.13082.
<Editors' Choice> Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
Kochin V, Nishikawa H
Nagoya J Med Sci. 2019; 81(1):1-18.
PMID: 30962651
PMC: 6433633.
DOI: 10.18999/nagjms.81.1.1.
Major histocompatibility complex class I diversity limits the repertoire of T cell receptors.
Migalska M, Sebastian A, Radwan J
Proc Natl Acad Sci U S A. 2019; 116(11):5021-5026.
PMID: 30796191
PMC: 6421458.
DOI: 10.1073/pnas.1807864116.
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D
Front Immunol. 2018; 9:947.
PMID: 29770138
PMC: 5941317.
DOI: 10.3389/fimmu.2018.00947.
The opposing roles of CD4 T cells in anti-tumour immunity.
Ahrends T, Borst J
Immunology. 2018; .
PMID: 29700809
PMC: 6050207.
DOI: 10.1111/imm.12941.
Immunotherapy in ovarian cancer.
Odunsi K
Ann Oncol. 2017; 28(suppl_8):viii1-viii7.
PMID: 29232467
PMC: 5834124.
DOI: 10.1093/annonc/mdx444.
Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status.
Shiohama Y, Naito T, Matsuzaki T, Tanaka R, Tomoyose T, Takashima H
Virol J. 2017; 14(1):130.
PMID: 28716148
PMC: 5512893.
DOI: 10.1186/s12985-017-0802-9.
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.
Park J, Cheung N
Cancer Treat Rev. 2017; 58:22-33.
PMID: 28622628
PMC: 5524462.
DOI: 10.1016/j.ctrv.2017.05.006.